XORTX THERAPEUTICS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.5 CAD | -3.31% |
|
-14.00% | +20.69% |
| Apr. 22 | XORTX Therapeutics Announces Publication of Key Research in ADPKD in Peer-reviewed Journal | MT |
| Apr. 08 | XORTX Therapeutics Inc. Appoints Abigail Jenkins to the Board of Directors | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.
Calendar
2024-05-28
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.62
Average target price
-
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +20.69% | 7.66M | |
| -1.93% | 103B | |
| +0.27% | 95.71B | |
| +1.69% | 22.02B | |
| -17.16% | 20.9B | |
| -9.30% | 17.85B | |
| -41.01% | 16.21B | |
| -14.98% | 15.52B | |
| +3.51% | 13.86B | |
| +34.86% | 12.04B |
- Stock Market
- Equities
- XRTX Stock
- News XORTX Therapeutics Inc.
- XORTX Therapeutics Appoints Former Pfizer Executive Stacy Evans as Chief Business Officer
